Quantcast
Last updated on April 20, 2014 at 7:43 EDT

Latest Vancomycin Stories

2012-10-02 02:29:56

SAN DIEGO, Oct. 2, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today the implementation of an initiative designed to accelerate and expand patient access to DIFICID® (fidaxomicin) tablets. Separately, and consistent with its goal of improving awareness and understanding of the disease, Optimer is also announcing a new project analyzing the burden of Clostridium difficile infection (CDI). (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)...

2012-08-07 10:25:25

CORAL SPRINGS, Fla., Aug. 7, 2012 /PRNewswire/ -- Digestive CARE(TM), a medical group of 52 gastroenterologists in Broward and Palm Beach County, today announced that they are the first gastroenterology group in South Florida to offer Fecal Transplant therapy to patients with Fulminant or Refractory Pseudomembraneous Colitis. Pseudomembranous colitis has dramatically increased in frequency and severity over the past ten years. Coincident with this, a dramatic increase has been seen in...

2012-07-17 02:27:55

SAN FRANCISCO, July 17, 2012 /PRNewswire/ -- Keiretsu Forum's members recently made a significant investment of more than $3 million to take lead on a Series B fundraising round for Savara Pharmaceuticals. Keiretsu Forum is the world's largest private equity angel investment network. Savara is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. "The opportunity to invest in...

2012-07-13 06:24:24

PHILADELPHIA, July 13, 2012 /PRNewswire/ -- The law firm of Berger & Montague, P.C. was the first law firm to file a class action against Viropharma Incorporated and Vincent J. Milano in Eastern District of Pennsylvania on May 17, 2012, Docket Number 2:12-CV-02714 on behalf of all investors who purchased shares of Viropharma ("VPHM") between December 14, 2011 and April 9, 2012. The complaint alleges that on December 14, 2011 Viropharma issued a press release announcing the...

2012-07-05 02:24:10

SAN DIEGO, July 5, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that DIFICID® (fidaxomicin) tablets were approved by Health Canada for the treatment of Clostridium difficile infection (CDI), in adults 18 years of age and older and that DIFICID is now available to treat patients in Canada. The approval was based on Health Canada's evaluation of two large, multi-national, Phase 3 clinical trials demonstrating that DIFICID was as effective as...

2012-07-05 02:24:00

TORONTO, July 5, 2012 /CNW/ - Optimer Pharmaceuticals Canada, Inc. announced today the approval of DIFICID (fidaxomicin) by Health Canada for the treatment of Clostridium difficile infection (CDI) in patients 18 years of age and older. DIFICID was approved in Canada on a priority basis recognizing the critical need for new options to treat this disease and is the first new treatment for CDI in over 20 years. Two large double-blind, comparative, randomized clinical studies were...

2012-06-12 02:26:23

AUSTIN, Texas, June 12, 2012 /PRNewswire/ -- Savara Pharmaceuticals, an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions, today announced positive top-line data from its AeroVanc Phase I clinical study in patients with cystic fibrosis (CF). AeroVanc, a dry powder formulation of vancomycin, is the first inhaled antibiotic being developed for the treatment of respiratory methicillin-resistant...

2012-06-12 02:26:22

AUSTIN, Texas, June 12, 2012 /PRNewswire/ -- Savara Pharmaceuticals, an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions, today announced that it has raised $8.6 million in the first closing of a Series B round of financing. The Keiretsu Forum, comprising accredited private equity investors, led the financing with participation from Savara's existing investors. Savara will use the proceeds from this...

2012-06-04 17:52:12

Canada should ban off-label use of antibiotics in farm animals because it contributes significantly to antibiotic resistance in humans, states an editorial in CMAJ (Canadian Medical Association Journal). Off-label use means using antibiotics for purposes other than those indicated on the label. "Of greatest concern is the promotion of resistance to antibiotics that may currently represent the last resort for treating some highly resistant infections in humans," writes Barbara Sibbald,...

2012-06-04 10:22:46

PHILADELPHIA, June 4, 2012 /PRNewswire-USNewswire/ --On May 17, 2012 the law firm of Berger & Montague, P.C. filed a class action Complaint against ViroPharma Incorporated (VPHM)"("ViroPharma" or the "Company") and Vincent J. Milano, its President, Chief Executive Officer and Chairman of its Board of Directors, in the Eastern District of Pennsylvania, No. 2:12-CV-02714 on behalf of all purchasers of ViroPharma securities between December 14, 2011 and April 9, 2012, inclusive (the "Class...


Latest Vancomycin Reference Libraries

0_4d46cc72a490344d44ba78359f528175
2011-04-26 21:07:20

Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...

0_71ad70ea6f0948a7e84406e760c7f5a4
2011-04-15 14:36:05

Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...

More Articles (2 articles) »